Patient
SITE015-0023
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2025-09-24
Adverse events
7
Serious AEs
2
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-11 (study day 321); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 309); relationship: not assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 226); relationship: RELATED; serious criteria: hospitalization
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-06 (study day 163); relationship: RELATED
Grade 4 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-09-05 (study day 162); relationship: not assessed; serious criteria: life-threatening
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-25 (study day 120); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-12 (study day 46); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.